Cdmo was Lifecore Biomedical, Inc. \De\’s largest product and service line in fiscal 2025, bringing in $90.10M of $128.87M (70%).
| Product and Service | FY 2018 | FY 2019 | FY 2020 | FY 2020 | FY 2020 | FY 2021 | FY 2021 | FY 2021 | FY 2022 | FY 2022 | FY 2022 | FY 2022 | FY 2023 | FY 2023 | FY 2024 | FY 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Fresh Packaged Salads & Vegetables | — | — | — | — | — | — | — | — | ||||||||
| Olive Oil & Wine Vinegars | — | — | — | — | — | — | — | — | ||||||||
| Other | $8.43M | $1.91M | $19.65M | — | — | — | — | — | ||||||||
| Cdmo | — | $86.35M | — | — | — | $76.38M | $96.62M | $90.10M | ||||||||
| Contract Development & Manufacturing Organization | $88.79M | — | $18.27M | — | — | — | — | — | ||||||||
| Contract Development & Manufacturing Organization ("Cdmo") | — | — | — | — | — | — | — | — | ||||||||
| Contract Development & Manufacturing Organization And Fermentation | $116.56M | — | $23.72M | $21.86M | $72.12M | — | — | — | ||||||||
| Ha Manufacturing | — | — | — | — | — | — | $31.65M | $38.77M | ||||||||
| Fermentation | $27.77M | $23.01M | $5.46M | — | — | $26.89M | — | — | ||||||||
| Avocado Products | — | — | $0 | — | — | — | — | — | ||||||||
| Olive Oil & Vinegars | $7.02M | — | $2.56M | — | — | — | — | — | ||||||||
| Technology | $1.42M | — | — | — | — | — | — | — | ||||||||
| Total | $249.98M | $111.27M | $69.66M | $21.86M | $72.12M | $103.27M | $128.26M | $128.87M |
Lifecore Biomedical, Inc. \De\ brought in $128.87M from its two product and service lines in fiscal 2025, the year ended May 25, 2025. That was up 0.5% from $128.26M in fiscal 2024. Cdmo was the largest at $90.10M (69.9%), ahead of Ha Manufacturing at $38.77M (30.1%).
Compared with fiscal 2024, Ha Manufacturing grew 22.5% to $38.77M, while Cdmo fell 6.7% to $90.10M.
Lifecore Biomedical, Inc. \De\ began breaking out Ha Manufacturing in fiscal 2024, when it brought in $31.65M. Lifecore Biomedical, Inc. \De\ stopped reporting Contract Development & Manufacturing Organization And Fermentation ($72.12M in fiscal 2023), Fermentation ($26.89M in fiscal 2023), Other ($19.65M in fiscal 2022) and three others as separate lines.
Revenues Recognized At A Point In Time was Lifecore Biomedical, Inc. \De\’s largest revenue line in fiscal 2025, bringing in $105.67M of $128.87M (82%).
| Timing of Transfer of Good or Service | FY 2022 | FY 2023 | FY 2024 | FY 2025 |
|---|---|---|---|---|
| Revenues Recognized At A Point In Time | — | — | $98.90M | $105.67M |
| Transferred At Point In Time | $73.60M | $74.60M | — | — |
| Revenues Recognized Over Time | — | — | $29.36M | $23.19M |
| Transferred Over Time | $35.80M | $28.60M | — | — |
| Total | $109.40M | $103.20M | $128.26M | $128.87M |
Lifecore Biomedical, Inc. \De\ brought in $128.87M from its two revenue lines in fiscal 2025, the year ended May 25, 2025. That was up 0.5% from $128.26M in fiscal 2024. Revenues Recognized At A Point In Time was the largest at $105.67M (82.0%), ahead of Revenues Recognized Over Time at $23.19M (18.0%).
Compared with fiscal 2024, Revenues Recognized At A Point In Time grew 6.8% to $105.67M, while Revenues Recognized Over Time fell 21.0% to $23.19M.
Lifecore Biomedical, Inc. \De\ began breaking out Revenues Recognized At A Point In Time in fiscal 2024 and Revenues Recognized Over Time in fiscal 2024. Lifecore Biomedical, Inc. \De\ stopped reporting Transferred At Point In Time ($74.60M in fiscal 2023) and Transferred Over Time ($28.60M in fiscal 2023) as separate revenue lines.
Nonrelated Party was Lifecore Biomedical, Inc. \De\’s largest revenue line in fiscal 2025, bringing in $72.33M of $128.87M (56%).
| Related and Nonrelated Parties | FY 2022 | FY 2023 | FY 2024 | FY 2025 |
|---|---|---|---|---|
| Nonrelated Party | $111.27M | $99.25M | $77.67M | $72.33M |
| Related Party | — | $4.02M | $50.59M | $56.54M |
| Total | $111.27M | $103.27M | $128.26M | $128.87M |
Lifecore Biomedical, Inc. \De\ brought in $128.87M from its two revenue lines in fiscal 2025, the year ended May 25, 2025. That was up 0.5% from $128.26M in fiscal 2024. Nonrelated Party was the largest at $72.33M (56.1%), ahead of Related Party at $56.54M (43.9%).
Compared with fiscal 2024, Related Party grew 11.8% to $56.54M, while Nonrelated Party fell 6.9% to $72.33M.
Lifecore Biomedical, Inc. \De\ began breaking out Related Party in fiscal 2023, when it brought in $4.02M.
Lifecore Biomedical, Inc. \De\ (LFCR) reports its revenue by product and service, by timing of transfer of good or service and by related and nonrelated parties. In fiscal 2025, Cdmo was its largest product and service line, bringing in $90.10M (69.9% of the total), followed by Ha Manufacturing at $38.77M (30.1%).
Cdmo was Lifecore Biomedical, Inc. \De\'s largest product and service line in fiscal 2025, bringing in $90.10M, or 69.9% of the $128.87M total across its two product and service lines.
Revenues Recognized At A Point In Time was Lifecore Biomedical, Inc. \De\'s largest revenue line in fiscal 2025, bringing in $105.67M, or 82.0% of the $128.87M total across its two revenue lines.
Ha Manufacturing grew faster than Cdmo in fiscal 2025, up 22.5% from $31.65M to $38.77M. Cdmo fell 6.7% to $90.10M.
Every figure comes from Lifecore Biomedical, Inc. \De\'s annual financial filings, as reported. Each line keeps the name Lifecore Biomedical, Inc. \De\ gives it, and years follow its fiscal calendar.
Lifecore Biomedical, Inc. \De\'s revenue by product and service goes back to fiscal 2018, with figures through fiscal 2025. The latest four fiscal years are free to view, and the full history is available with a Business Quant subscription.